Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

NCT05640102 · clinicaltrials.gov ↗

RECRUITING

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Zanubrutinib

Sponsor

BeiGene